graph EGM comparisons
atezolizumab plus bevacizumab plus carboplatin plus paclitaxeltitleatezolizumab plus pemetrexed and platintitleatezolizumab plus carboplatin plus nab-paclitaxeltitlepembrolizumab plus SoCtitlepembrolizumab and pemetrexed plus platintitlecarboplatin plus nab-paclitaxeltitlepemetrexed plus platintitlebevacizumab plus carboplatin and paclitaxeltitleplacebo plus SoCtitleIMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 155/129IMpower-150 (ABCP vs BPC WT), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 356/336IMpower-130 (WT), 2019 NCT02367781 non squamous - mNSCLC - L1 - Wild Type (WT) 451/228IMpower-132 (WT), 0 NCT02657434 non squamous - mNSCLC - L1 - Wild Type (WT) 292/286KEYNOTE-021, 2016 NCT02039674 non squamous - mNSCLC - L1 - Wild Type (WT) 60/63KEYNOTE-189, 2018 NCT02578680 non squamous - mNSCLC - L1 - Wild Type (WT) 410/206

Pathology:  non squamous - mNSCLC - L1 - Wild Type (WT); 

non squamous - mNSCLC - L1 - Wild Type (WT)
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018IMpower-150 (ABCP vs BPC WT), 2018IMpower-130 (WT), 2019IMpower-132 (WT), 0KEYNOTE-021, 2016KEYNOTE-189, 2018
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel2T1T1
atezolizumab plus pemetrexed and platin1T1
atezolizumab plus carboplatin plus nab-paclitaxel1T1
pembrolizumab plus SoC1T1
pembrolizumab and pemetrexed plus platin1T1
carboplatin plus nab-paclitaxel0T0
pemetrexed plus platin0T0T0
bevacizumab plus carboplatin and paclitaxel0T0T0
placebo plus SoC0T0